Researchers unveiled a cell-free DNA fragmentomics approach that decodes tumor-linked nucleosomal patterns by analyzing the size distribution of circulating cfDNA fragments. The method links fragment sizes to their nucleosomal origins, enabling detection of tumor-associated “fragmentomic alterations” with high precision. The reporting describes a diagnostic pathway focused on fragment-size readouts rather than sequencing targets alone—positioning it as a potentially scalable complement to existing liquid biopsy workflows. The work is framed around improved signal specificity by capturing how nucleosome packaging patterns change in cancer. If validated clinically, fragmentomic profiling could help increase sensitivity for detecting malignancy and potentially refine monitoring approaches by leveraging biochemical features of cfDNA produced by tumor and non-tumor processes.